Policy of prioritizing research and development and paying no dividends for the time being
First written in FY2022. 9 of 10 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 2 of 19 companies on the "Worse" side.
31 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「The Company plans not to pay dividends for the time being and will prioritise R&D investment, on the assumption that funds will be allocated to clinical development expenses, R&D expenses, basic research expenses for intellectual property development, and other purposes.」
Reaffirms its policy of not paying dividends for the time being and prioritising the allocation of funds to clinical development, R&D and intellectual property development. - FY2026-H1RestatedAnnual report
「Dividend payments Not applicable」
No dividends were paid during the interim accounting period either, consistent with the policy of paying no dividends and prioritising the securing of funds for R&D and other purposes. - FY2025-H1RestatedAnnual report
「Dividend payments Not applicable.」
No dividends were paid during the interim accounting period, consistent with the policy of paying no dividends and prioritising the securing of funds for R&D and other purposes. - FY2024RestatedAnnual report
「To continue systematically conducting R&D activities involving substantial upfront investment, the Company plans not to pay dividends for the time being and will prioritise securing funds by retaining earnings for clinical trial research expenses, basic research expenses for scientific discoveries and intellectual property development, and other purposes.」
Reaffirms its policy of prioritising the securing of R&D funds and paying no dividends for the time being. - FY2024-Q3RestatedAnnual report
「Dividend payments Not applicable」
No dividends were paid during the cumulative third-quarter period, consistent with the policy of paying no dividends and prioritising the securing of funds for R&D and other purposes. - FY2024-Q2RestatedAnnual report
「Dividend payments Not applicable」
No dividends were paid during the cumulative second-quarter period, consistent with the policy of paying no dividends and prioritising the securing of funds for R&D and other purposes. - FY2024-Q1RestatedAnnual report
「Dividend payments Not applicable.」
No dividends were paid during the cumulative first-quarter period, consistent with the policy of paying no dividends and prioritising the securing of funds for R&D and other purposes. - FY2023RestatedAnnual report
「The Company plans not to pay dividends for the time being and will prioritise securing funds by retaining earnings for clinical trial research expenses, basic research expenses for scientific discoveries and intellectual property development, and other purposes.」
Reaffirms its policy of prioritising retained earnings for R&D and paying no dividends for the time being. - FY2023-Q2RestatedAnnual report
「Dividend payments Not applicable.」
States that no dividends were paid during the cumulative second-quarter period. - FY2022First statedAnnual report
「To continue systematically conducting R&D activities involving substantial upfront investment, the Company plans not to pay dividends for the time being and will prioritise securing funds by retaining earnings for clinical trial research expenses, basic research expenses for scientific discoveries and intellectual property development, and other purposes.」
Prioritises retaining earnings for clinical trials and basic research over shareholder returns.